logo-loader

OptiBiotix's Stephen O'Hara hails new safety status for LPLDL and recent awards

Published: 12:57 23 Oct 2019 BST

OptiBiotix Health PLC’s (LON:OPTI) Stephen O'Hara speaks to Proactive London's Andrew Scott soon after the news its LPLDL probiotic had been granted ‘generally recognised as safe’ (GRAS) status by the US Food and Drug Administration (FDA).

Its subsidiary, ProBiotix Health Ltd, received the GRAS after completing process validation under pharmaceutical good manufacturing practices (GMP), which test whether a drug substance such as LPLDL is produced consistently at pharmaceutical grade quality.

Chesnara reports strong 2023 results with improved cash generation and...

Chesnara PLC (LSE:CSN) chief executive Steve Murray discusses the company's full-year results for 2023 with Proactive's Stephen Gunnion, describing them as strong and particularly highlighting £53 million in commercial cash generation and a dividend coverage of around 150%. The company has...

21 minutes ago